| Literature DB >> 35844391 |
Manal M Elbandrawy1, Osama Sweef2,3, Doaa Elgamal1, Tarek M Mohamed1, Rehab M Elgharabawy4,5.
Abstract
Background: Type 2 diabetes (T2DM) is a chronic metabolic disorder. Although therapeutic pharmaceutical agents continue to advance, herbal medicines are potential complementary treatments for the promotion of glucose homeostasis, with minimal adverse effects. Conventionally, ellagic acid (EA) has been utilized for the therapy of a range of pathologies owing to its anti-inflammatory and anti-diabetic actions. Objective: The aim of this study is to determine the activity of EA on serum α-amylase and lipase titers, and on pancreatic tumor necrosis factor-α (TNF-α), proliferating cell nuclear antigen (PCNA) and interleukin-6 (IL-6) concentrations using the streptozocin-induced T2DM rodent model.Entities:
Keywords: Ellagic acid; Immunohistochemistry; Pancreas β-cells; Pancreatic enzymes; T2DM
Year: 2022 PMID: 35844391 PMCID: PMC9280239 DOI: 10.1016/j.sjbs.2022.03.016
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 2213-7106 Impact factor: 4.052
Phytochemical profile of the methanolic extract of strawberry fruit.
| Total polyphenol content | 642.6 mg gallic acid equivalent per 100 g sample |
| Total flavonoid content | 98.5 mg quercetin equivalent per 100 g sample |
| Antioxidant activity | 59.81% |
| DPPH radical scavenging activity IC50 (dry sample) | 7.5 |
Fig. 1FTIR spectra of the ellagic acid.
Impact of treatment with ellagic acid extract on serum FBG, α-amylase and lipase titres in the differing rodent cohorts.
| Control | Ellagic | Diabetic | Co-treated | Post-treated | |
|---|---|---|---|---|---|
| Lipase (IU/L) | 46.0#±1.2 | 45.3#±0.9 | 26.25*±0.5 | 43.33#±0.8 | 46.33#±1.9 |
| α-amylase (IU/L) | 647.5#±2.0 | 632.5#±1.3 | 815.7*±3.2 | 621.7#±1.5 | 524.5#±2.5 |
| FBG (mg/dl) | 89.7#±0.6 | 88.5#±0.8 | 292.1*±5.4 | 287.3*±3.5 | 182.3#*±10.1 |
Data are expressed as mean ± SEM of 10 observations. Significant difference from the control group at *p < 0.05. Significant difference from the diabetic group at #p < 0.05.
Fig. 2Photomicrographs of rat's pancreas sections in the different experimental groups stained with H&E. A&B: Normal structure of the pancreas consisted of exocrine (Acinar cells; AC) and endocrine (islets of Langerhans; L) portions in control and EA groups. C&D: Diabetic rats revealed decreased islets size, decreased β-cells number and degenerated entering connective tissue (arrows) sheet with irregular islets shape. E: Pancreatic sections in co-treated. F: Post treated revealed normal shape and increased β-cells number.
Fig. 3Photomicrographs of rats pancreas sections in the different experimental groups stained with PCNA. A-C: Strong positive reaction for PCNA immunoreactivity in control and ellagic acid groups. D: Mild to moderate PCNA positive reactions in diabetic group. E: Moderate PCNA positive reactions in co-treated grog. F: Strong PCNA positive reactions in post-treated group.
Fig. 4Photomicrographs of rat's pancreas (β-cell) sections in the different experimental groups stained with insulin immunoexpression. A&B: Strong positive reaction for insulin immunoreactivity in control and ellagic acid groups. C&D: Mild to moderate insulin positive reactions in diabetic group. E&F: Moderate to strong positive reactions for insulin in co-treated and post-treated groups.
Fig. 5Photomicrographs of rats pancreas (β-cell) sections in the different experimental groups stained with pro-inflammatory marker TNF-α immunoexpression. A&B: Negative or faint positive reaction for TNF-α immunoreactivity in control and ellagic acid groups. C: Moderate positive reaction for TNF-α immunoreactivity in diabetic group. D&E: Moderate positive reaction for TNF-α immunoreactivity in co-treated and post-treated groups.
Fig. 6Photomicrographs of rats pancreas (β-cell) sections in the different experimental groups stained with IL-6 immunoexpression. A&B: Mild to moderate positive reaction for IL-6 immunoreactivity in control and ellagic acid group. C&D: strong positive reaction for IL-6 immunoreactivity in diabetic group. E: Moderate positive reaction for IL-6 immunoreactivity in co-treated group. F: Moderate positive reaction for IL-6 immunoreactivity in post-treated group.